Dermatology
| Psoriasis
Dermatology
Psoriasis
Secukinumab treatment results in improvements in DLQI associated with low absolute PASI scores: 24-month follow-up from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
book_2
Source:
EADV Virtual - Poster session
calendar_today
Published on Medfyle:
November 2020
headphones
4
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Secukinumab is a fully human monoclonal antibody targeting IL-17A.
- This retrospective analysis evaluated 1,679 patients enrolled in BADBIR and receiving secukinumab; of these, 69.8% were biologic-naïve.
- Over 24 months, secukinumab demonstrated improvement in absolute PASI and quality of life.
- There was a difference in the correlation of DLQI with clinical outcomes between biologic-naïve and -experienced patients, suggesting increased expectations in later lines of treatment.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
A. Bewley, MD
Whipps Cross and Royal London Hospitals, Barts Health NHS Trust, London UK